Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

193.33 -1.05 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 453,244
Open 192.49
Bid (Size) 191.18 (1)
Ask (Size) 220.00 (1)
Prev. Close 194.38
Today's Range 189.00 - 195.58
52wk Range 119.76 - 322.67
Shares Outstanding 17,103,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
6 Stocks Positioned to Soar as Investors Focus on MASH
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of... 
Via TheNewswire.com
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades. 
Via InvestorPlace

Performance

YTD
-14.78%
-14.78%
1 Month
-21.92%
-21.92%
3 Month
-16.01%
-16.01%
6 Month
+54.78%
+54.78%
1 Year
-37.08%
-37.08%

More News

Read More
2 Under-the-Radar Growth Stocks to Consider
Via The Motley Fool
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
Via The Motley Fool
1 No-Brainer Growth Stock to Buy Now
Via The Motley Fool
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
Via The Motley Fool
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading
Via Investor Brand Network
The 3 Best Biotech Stocks to Buy in April 2024
Via InvestorPlace
2 Top Biotech Buyout Candidates
Via Talk Markets
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Via The Motley Fool
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
Via The Motley Fool
7 Stocks That Will Drive the Weight Loss Drugs Market
Via MarketBeat
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
Via The Motley Fool
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Via The Motley Fool
Exposures Product Safety
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Via The Motley Fool
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring
Via Benzinga
Exposures Product Safety
Why Is Geron (GERN) Stock Up 94% Today?
Via InvestorPlace
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.